Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority trial of LOQOA (S-flurbiprofen plaster) vs existing NSAID treatment in knee osteoarthritis
jRCTs021180050Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of esflurbiprofen in knee osteoarthritis (OA) (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in pain VAS at 4 weeks. Started Dec 2017; status: completed.
02
Drugs
esflurbiprofen
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCTs021180050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180050.